Therapure Biopharma Postpones IPO

Photo of Chris Lange
By Chris Lange Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Therapure Biopharma Postpones IPO

© Thinkstock

The initial public offering (IPO) market has grown cold as global markets have been sliding in 2016, and many companies are choosing to postpone their IPOs for more favorable market conditions. Therapure Biopharma is no exception. The company announced that, due to current conditions in capital markets, it would postpone its offering.

While the company is performing above expectations and investor feedback about the quality of management and the company was very positive, Therapure makes this decision in light of the current market environment, in which no IPOs were concluded in the United States or Canada in January.

The underwriters for the offering are GMP Securities, CIBC World Markets and National Bank Financial.
[nativounit]
For some background on the company:

Therapure is a biopharmaceutical company focused on manufacturing complex biologics for its customers and on developing, manufacturing and selling its own blood and plasma-related therapeutic products. Its passion for quality and patient safety underpins everything it does in its three divisions: Therapure Biomanufacturing, an award-winning contract development and manufacturing division; Therapure Biologics, a division focused on using its proprietary PlasmaCap EBA technology to develop a portfolio of plasma-derived pharmaceutical products; and Therapure Innovations, a proprietary therapeutics and platform technologies research and development division.

Contact [email protected] for any questions or corrections.

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Continue Reading

Top Gaining Stocks

GLW Vol: 24,307,400
KLA
KLAC Vol: 14,628,648
WDC Vol: 11,268,872
AMAT Vol: 14,164,881
AXON Vol: 1,847,989

Top Losing Stocks

HON Vol: 7,773,157
CTRA Vol: 73,319,495
SMCI Vol: 91,227,161
CPRT Vol: 18,101,097
ULTA Vol: 895,681